Future trends in human brucellosis treatment

Bibliography

• PAPPAS G, AKRITIDIS N, BOSILKOVSKI M et al.: Brucellosis. N. Engl. J. Med. (2005) 352:2325-2336.
   PubMed Web of Science ®Google Scholar
• PAPPAS G, PAPADIMITRIOU P, CHRISTOU L et al.: The new global map of human brucellosis. Lancet Infect. Dis. (2006) 6:91-99.
   PubMed Web of Science ®Google Scholar
• MEMISH ZA, BALKHY HH: Brucellosis and international travel. J. Travel. Med. (2004) 11:49-55.
   PubMed Web of Science ®Google Scholar
• PAPPAS G, PANAGOPOULOU P, CHRISTOU L et al.: Category B potential bioterrorism agents: bacteria, viruses, toxins, and foodborne and waterborne pathogens. Infect. Dis. Clin. North Am. (2006) 20:395-421.
   Google Scholar
• BOUZA E, SANCHEZ-CARRILLO C, HERNANGOMEZ S et al.: Laboratory-acquired brucellosis: a Spanish national survey. J. Hosp. Infect. (2005) 6:80-83.
   Google Scholar
• GODFROID J: Brucellosis in wildlife. Rev. Sci. Tech. (2002) 21:277-286.
   Google Scholar
• CELLI J, GORVEL JP: Organelle robbery: Brucella interactions with the endoplasmic reticulum. Curr. Opin. Microbiol. (2004) 7:93-97.
   Web of Science ®Google Scholar
• BILLARD E, CAZEVIEILLE C, DORNAND J et al.: High susceptibility of human dendritic cells to invasion by the intracellular pathogens Brucella suis, B. abortus, and B. melitensis. Infect. Immun. (2005) 73:8418-8424.
   Web of Science ®Google Scholar
• MAGOFFIN RL, SPINK WW: The protection of intracellular Brucella against streptomycin alone and in combination with other antibiotics. J. Lab. Clin. Med. (1951) 37:924-930.
   Google Scholar
• PAPPAS G, AKRITIDIS N, TSIANOS E: Effective treatments in the management of brucellosis. Expert Opin. Pharmacother. (2005) 6:201-209.
   Google Scholar
• PHILIPPON AM, PLOMMET MG, KAZMIERCZAK A et al.: Rifampin in the treatment of experimental brucellosis in mice and guinea pigs. J. Infect. Dis. (1977) 136:481-488.
   PubMedGoogle Scholar
• SOLERA J, RODRIGUEZ-ZAPATA M, GEIJO P et al.: Doxycycline–rifampin versus doxycycline–streptomycin in treatment of human brucellosis due to Brucella melitensis. Antimicrob. Agents Chemother. (1995) 39:2061-2067.
   Web of Science ®Google Scholar
• KHAN MY, MAH MW, MEMISH ZA: Brucellosis in pregnant women. Clin. Infect. Dis. (2001) 32:1172-1177.
   Google Scholar
• LUBANI MM, DUDIN KI, SHARDA DC et al.: A multicenter therapeutic study of 1100 children with brucellosis. Pediatr. Infect. Dis. J. (1989) 8:75-78.
   Google Scholar
• FALAGAS ME, BLIZIOTIS IA: Quinolones for treatment of human brucellosis: critical review of the evidence from microbiological and clinical studies. Antimicrob. Agents Chemother. (2006) 50:22-33.
   Web of Science ®Google Scholar
• SOLERA J, MARTINEZ-ALFARO E, ESPINOSA A: Recognition and optimum treatment of brucellosis. Drugs (1997) 53:245-256.
   PubMed Web of Science ®Google Scholar
• SOLERA J, LOZANO E, MARTINEZ-ALFARO E et al.: Brucellar spondylitis: review of 35 cases and literature survey. Clin. Infect. Dis. (1999) 29:1440-1449.
   Google Scholar
• PAPPAS G, SEITARIDIS S, AKRITIDIS N et al.: Treatment of Brucella spondylitis: lessons from an impossible meta-analysis and initial report of efficacy of a fluoroquinolone-containing regimen. Int. J. Antimicrob. Agents (2004) 24:502-507.
   Web of Science ®Google Scholar
• SHAKIR RA, AL-DIN ASN, ARAJ GF et al.: Clinical categories of neurobrucellosis. A report on 19 cases. Brain (1987) 110:213-23.
   PubMed Web of Science ®Google Scholar
• OZSOYLER I, YILIK L, BOZOK S et al.: Brucella endocarditis: the importance of surgical timing after medical treatment (five cases). Prog. Cardiovasc. Dis. (2005) 47:226-229.
   Google Scholar
• NAVARRO E, SEGURA JC, CASTANO MJ et al.: Use of real-time quantitative polymerase chain reaction to monitor the evolution of Brucella melitensis DNA load during therapy and post-therapy follow-up in patients with brucellosis. Clin. Infect. Dis. (2006) 42:1266-1273
   Google Scholar
• HASANJANI ROUSHAN MR, MOHRAZ M, HAJIAHMADI M et al.: Efficacy of gentamicin plus doxycycline versus streptomycin plus doxycycline in the treatment of brucellosis in humans. Clin. Infect. Dis. (2006) 42:1075-1080.
   Google Scholar
• ROUSHAN MR, GANGI SM, AHMADI SA: Comparison of the efficacy of 2 months of treatment with co-trimoxazole plus doxycycline versus co-trimoxazole plus rifampin in brucellosis. Swiss Med. Wkly (2004) 134:564-568.
   PubMed Web of Science ®Google Scholar
• MARIANELLI C, CIUCHINI F, TARANTINO M et al.: Genetic bases of the rifampin resistance phenotype in Brucella spp. J. Clin. Microbiol. (2004) 42:5439-5443.
   Google Scholar
• PRIOR S, GAMAZO C, IRACHE JM et al.: Gentamicin encapsulation in PLA/PLGA microspheres in view of treating Brucella infections. Int. J. Pharm. (2000) 196:115-125.
   Web of Science ®Google Scholar
• PRIOR S, GANDER B, LECAROZ C et al.: Gentamicin-loaded microspheres for reducing the intracellular Brucella abortus load in infected monocytes. J. Antimicrob. Chemother. (2004) 53:981-988.
   Google Scholar
• PRIOR S, GANDER B, IRACHE JM et al.: Gentamicin-loaded microspheres for treatment of experimental Brucella abortus infection in mice. J. Antimicrob. Chemother. (2005) 55:1032-1036.
   Google Scholar
• SOLERA J, BEATO JL, MARTINEZ-ALFARO E et al.: Azithromycin and gentamicin therapy for the treatment of humans with brucellosis. Clin. Infect. Dis. (2001) 32:506-509.
   Google Scholar
• AKOVA M, GUR D, LIVERMORE DM et al.: In vitro activities of antibiotics alone and in combination against Brucella melitensis at neutral and acidic pHs. Antimicrob. Agents Chemother. (1999) 43:1298-300.
   Web of Science ®Google Scholar
• RAOULT D, HOUPIKIAN P, TISSOT DUPONT H et al.: Treatment of Q fever endocarditis: comparison of 2 regimens containing doxycycline and ofloxacin or hydroxychloroquine. Arch. Intern. Med. (1999) 15:167-173.
   Google Scholar
• ZHANEL GG, KARLOWSKY JA, RUBINSTEIN E et al.: Tigecycline: a novel glycylcycline antibiotic. Expert Rev. Anti-Infect. Ther. (2006) 4:9-25.
   Google Scholar
• LIVERMORE DM: Tigecycline: what is it, and where should it be used? J. Antimicrob. Chemother. (2005) 56:611-614.
   Google Scholar
• NATHWANI D: Tigecycline: clinical evidence and formulary positioning. Int. J. Antimicrob. Agents (2005) 25:185-192.
   Google Scholar
• LOPEZ-GONI I, GUZMAN-VERRI C, MANTEROLA L et al.: Regulation of Brucella virulence by the two-component system BvrR/BvrS. Vet. Microbiol. (2002) 90:329-339.
   Google Scholar
• GORVEL JP, MORENO E: Brucella intracellular life: from invasion to intracellular replication. Vet. Microbiol. (2002) 90:281-297.
   Google Scholar
• BOURZAC KM, GUILLEMIN K: Helicobacter pylori-host cell interactions mediated by type IV secretion. Cell Microbiol. (2005) 7:911-919.
   Web of Science ®Google Scholar
• BOSCHIROLI ML, OUAHRANI-BETTACHE S, FOULONGNE V et al.: Type IV secretion and Brucella virulence. Vet. Microbiol. (2002) 90:341-348.
   Google Scholar
• FOULONGNE V, BOURG G, CAZEVIEILLE C et al.: Identification of Brucella suis genes affecting intracellular survival in an in vitro human macrophage infection model by signature-tagged transposon mutagenesis. Infect. Immun. (2000) 68:1297-1303.
   Web of Science ®Google Scholar
• CONNOLLY JP, COMERCI D, ALEFANTIS TG et al.: Proteomic analysis of Brucella abortus cell envelope and identification of immunogenic candidate proteins for vaccine development. Proteomics (2006) 6(13):3767-3780.
   PubMed Web of Science ®Google Scholar
• YINGST S, HOOVER DL: T cell immunity to brucellosis. Crit. Rev. Microbiol. (2003) 29:313-331.
   Google Scholar
• BOURA P, RAPTOPOULOU-GIGI M, ACRIVIADIS E et al.: Reevaluation of the effect of levamisole in chronic brucellosis: in vitro and in vivo effect on monocyte phagocytosis. J. Immunopharmacol. (1984) 6:135-146.
   Google Scholar
• IRMAK H, BUZGAN T, KARAHOCAGIL MK et al.: The effect of levamisole combined with the classical treatment in chronic brucellosis. Tohoku J. Exp. Med. (2003) 201:221-228
   PubMed Web of Science ®Google Scholar
• MUKOVOZOVA LA: Effect of levamisole on the cellular immunity indices of patients with active forms of brucellosis. Zh. Mikrobiol. Epidemiol. Immunobiol. (1988) 6:61-65.
   Google Scholar
• PEREZ-GALLARDOL, BLANCO ML, SORIA H et al.: Displacement of rifampicin bound to serum proteins by addition of levamisole. Biomed. Pharmacother. (1992) 46:173-174.
   Google Scholar
• DIZER U, HAYAT L, BECKER CM et al.: The effect of the doxycycline–rifampicin and levamisole combination on lymphocyte subgroups and functions of phagocytic cells in patients with chronic brucellosis. Chemotherapy (2005) 51:27-31.
   PubMed Web of Science ®Google Scholar
• PRINTZIS S, RAPTOPOULOU-GIGI M, ORPHANOU-KOUMERKERIDOU H et al.: Immunotherapy in chronic brucellosis. Effect of levamisole and interferon; mechanisms of action and clinical value. Immunopharmacol. Immunotoxicol. (1994) 16:679-693.
   Google Scholar
• SCHURIG GG, SRIRANGANATHAN N, CORBEL MJ: Brucellosis vaccines: past, present and future. Vet. Microbiol. (2002) 90:479-496.
   Google Scholar
• GUIHOT A, BOSSI P, BRICAIRE F: Bioterrorism with brucellosis. Presse. Med. (2004) 33:119-122.
   PubMedGoogle Scholar
• KO J, SPLITTER GA: Molecular host-pathogen interaction in brucellosis: current understanding and future approaches to vaccine development for mice and humans. Clin. Microbiol. Rev. (2003) 16:65-78.
   Google Scholar
• TABATABAI LB, PUGH GW Jr: Modulation of immune responses in Balb/c mice vaccinated with Brucella abortus Cu–Zn superoxide dismutase synthetic peptide vaccine. Vaccine (1994) 12:919-924.
   PubMed Web of Science ®Google Scholar
• ONATE AA, VEMULAPALLI R, ANDREWS E et al.: Vaccination with live Escherichia coli expressing Brucella abortus Cu–Zn superoxide dismutase protects mice against virulent B. abortus. Infect. Immun. (1999) 67:986-988.
   Web of Science ®Google Scholar
• VEMULAPALLI R, HE Y, CRAVERO S et al.: Overexpression of protective antigen as a novel approach to enhance vaccine efficacy of Brucella abortus strain RB51. Infect. Immun. (2000) 68:3286-3289.
   Web of Science ®Google Scholar
• HE Y, VEMULAPALLI R, SCHURIG GG: Recombinant Ochrobactrum anthropi expressing Brucella abortus Cu–Zn superoxide dismutase protects mice against B. abortus infection only after switching of immune responses to TH1 type. Infect. Immun. (2002) 70:2535-2543.
   Web of Science ®Google Scholar
• ONATE AA, CESPEDES S, CABRERA A et al.: A DNA vaccine encoding Cu–Zn superoxide dismutase of Brucella abortus induces protective immunity in BALB/c mice. Infect. Immun. (2003) 71:4857-4861.
   Web of Science ®Google Scholar
• MUNOZ-MONTESINO C, ANDREWS E, RIVERS R et al.: Intraspleen delivery of a DNA vaccine coding for superoxide dismutase (SOD) of Brucella abortus induces SOD-specific CD4+ and CD8+ T cells. Infect. Immun. (2004) 72:2081-2087.
   Web of Science ®Google Scholar
• ONATE AA, DONOSOG, MORAGA-CID G et al.: An RNA vaccine based on recombinant Semliki Forest virus particles expressing the Cu–Zn superoxide dismutase protein of Brucella abortus induces protective immunity in BALB/c mice. Infect. Immun. (2005) 73:3294-3300.
   Web of Science ®Google Scholar
• GONZALEZ-SMITH A, VEMULAPALLI R, ANDREWS E et al.: Evaluation of Brucella abortus DNA vaccine by expression of Cu–Zn superoxide dismutase antigen fused to IL-2. Immunobiology (2006) 211:65-74.
   PubMed Web of Science ®Google Scholar
• BHATTACHARJEE AK, VAN DE VERG L, IZADJOO MJ et al.: Protection of mice against brucellosis by intranasal immunization with Brucella melitensis lipopolysaccharide as a noncovalent complex with Neisseria meningitidis group B outer membrane protein. Infect. Immun. (2002) 70:3324-3329.
   Web of Science ®Google Scholar
• CASSATARO J, VELIKOVSKY CA, DELA BARRERA S et al.: A DNA vaccine coding for the Brucella outer membrane protein 31 confers protection against B. melitensis and B. ovis infection by eliciting a specific cytotoxic response. Infect. Immun. (2005) 73:6537-6546.
   Web of Science ®Google Scholar
• CASSATARO J, ESTEIN SM, PASQUEVICH KA et al.: Vaccination with the recombinant Brucella outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+ T helper 1 response that protects against Brucella melitensis infection. Infect. Immun. (2005) 73:8079-8088.
   Web of Science ®Google Scholar
• CASSATARO J, VELIKOVSKY CA, GIAMBARTOLOMEI GH et al.: Immunogenicity of the Brucella melitensis recombinant ribosome recycling factor-homologous protein and its cDNA. Vaccine (2002) 20:1660-1669.
   PubMed Web of Science ®Google Scholar
• VELIKOVSKY CA, CASSATARO J, GIAMBARTOLOMEI GH et al.: A DNA vaccine encoding lumazine synthase from Brucella abortus induces protective immunity in BALB/c mice. Infect. Immun. (2002) 70:2507-2511.
   Web of Science ®Google Scholar
• VELIKOVSKY CA, GOLDBAUM FA, CASSATARO J et al.: Brucella lumazine synthase elicits a mixed TH1-TH2 immune response and reduces infection in mice challenged with Brucella abortus 544 independently of the adjuvant formulation used. Infect. Immun. (2003) 71:5750-5755.
   Web of Science ®Google Scholar
• VEMULAPALLI R, CRAVERO S, CALVERT CL et al.: Characterization of specific immune responses of mice inoculated with recombinant vaccinia virus expressing an 18-kilodalton outer membrane protein of Brucella abortus. Clin. Diagn. Lab. Immunol. (2000) 7:114-118.
   Google Scholar
• STABEL TJ, MAYFIELD JE, TABATABAI LB et al.: Oral immunization of mice with attenuated Salmonella typhimurium containing a recombinant plasmid which codes for production of a 31-kilodalton protein of Brucella abortus. Infect. Immun. (1990) 58:2048-2055.
   Web of Science ®Google Scholar
• LECLERQ S, HARMS JS, ROSINHA GM et al.: Induction of a TH1-type of immune response but not protective immunity by intramuscular DNA immunisation with Brucella abortus GroEL heat-shock gene. J. Med. Microbiol. (2002) 51:20-26.
   Google Scholar
• BAE JE, SCHURIG GG, TOTH TE: Mice immune responses to Brucella abortus heat shock proteins. Use of baculovirus recombinant-expressing whole insect cells, purified Brucella abortus recombinant proteins, and a vaccinia virus recombinant as immunogens. Vet. Microbiol. (2002) 88:189-202.
   Google Scholar
• AL-MARIRI A, TIBOR A, MERTENS P et al.: Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant. Infect. Immun. (2001) 69:4816-4822.
   Web of Science ®Google Scholar
• AL-MARIRI A, TIBOR A, MERTENS P et al.: Induction of immune response in BALB/c mice with a DNA vaccine encoding bacterioferritin or P39 of Brucella spp. Infect. Immun. (2001) 69:6264-6270.
   Web of Science ®Google Scholar
• AL-MARIRI A, TIBOR A, LESTRATE P et al.: Yersinia enterocolitica as a vehicle for a naked DNA vaccine encoding Brucella abortus bacterioferritin or P39 antigen. Infect. Immun. (2002) 70:1915-1923.
   Web of Science ®Google Scholar
• OLIVEIRA SC, SPLITTER GA: Immunization of mice with recombinant L7/L12 ribosomal protein confers protection against Brucella abortus infection. Vaccine (1996) 14:959-962
   PubMed Web of Science ®Google Scholar
• KURAR E, SPLITTER GA: Nucleic acid vaccination of Brucella abortus ribosomal L7/L12 gene elicits immune response. Vaccine (1997) 15:1851-1857.
   PubMed Web of Science ®Google Scholar
• PONTES DS, DORELLA FA, RIBEIRO LA et al.: Induction of partial protection in mice after oral administration of Lactococcus lactis producing Brucella abortus L7/L12 antigen. J. Drug Target (2003) 11:489-493.
   PubMed Web of Science ®Google Scholar
• BALOGLU S, BOYLE SM, VEMULAPALLI R et al.: Immune responses of mice to vaccinia virus recombinants expressing either Listeria monocytogenes partial listeriolysin or Brucella abortus ribosomal L7/L12 protein. Vet. Microbiol. (2005) 109:11-17.
   Google Scholar
• LUO DY, LI P, XING L et al.: DNA vaccine encoding L7/L12-P39 of Brucella abortus induces protective immunity in BALB/c mice. Chin. Med. J. (Engl.) (2006) 119:331-334.
   Google Scholar
• CHU RS, TARGONI OS, KRIEG AM et al.: CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (TH1) immunity. J. Exp. Med. (1997) 186:1623-1631.
   PubMed Web of Science ®Google Scholar
• LEITNER WW: Myth, menace or medical blessing? The clinical potential and problems of genetic vaccines. Expert Opin. Biol. Ther. (2003) 3:1-4.
   Google Scholar